CROMSOURCE Expands in Poland

CROMSOURCE, which was formed roughly two years ago as a result of the acquisition of MSOURCE by CROM, has combined it’s presence in Poland with a new office in Warsaw. When CROM acquired MSOURCE, the latter contract research organisation (CRO) had been internationally active since 1994. Dr Oriana Zerbini, chief executive officer of CROMSOURCE, commented

Continue Reading

Roche and Chiasma Sign $585 Million Deal

Roche has teamed up with Chiasma to develop and market Octreolin, Chiasma’s investigational treatment for growth hormone disorders. Octreolin is oral form of the peptide octreotide, a somatostatin analogue which is currently only commercially available by injection and is marketed by Novartis as Sandostatin.  The drug is currently in a Phase III clinical trial for

Continue Reading

Tivozanib Matches Nexavar on Cancer Survival Rate

Astellas and Aveo Pharmaceuticals have announced that the overall survival (OS) data for their kidney cancer drug, tivozanib, which demonstrates that it matches a key competitor. Two-year data from the TIVO-1 clinical study shows that there is no statistically significant difference in the overall survival rate for tivozanib and Bayer/Onyx’s Nexavar, with both treatments providing

Continue Reading

Sanofi Earnings Knocked by Generics

Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant exchange rates), mainly as a result of

Continue Reading

Takeda Posts Q3 Financials, Boosted by Nesina and Pantoprazole Sales

Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (around $1.51 billion), however sales increased by 5.5% to 1.189 trillion yen.  Actos

Continue Reading

Watson Pharmaceuticals Renamed to Actavis and Announce Growth Strategy

Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding campaign that will guide the transition of their facilities, operations and commercial

Continue Reading

Scotland Unveils £21m Fund for Rare Diseases

A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014.  It will help cover successful new Individual Patient Treatment Requests for drugs that target rare

Continue Reading